L3MBTL2

Across TCGA pan-cancer cohorts, L3MBTL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated L3MBTL2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher L3MBTL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated L3MBTL2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and PDAC are the cancer types where L3MBTL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	1.000	0.890	.033	5	view →
HNSC	OS	Quartile	II,III,IV	0.735	0.458	.032	2	view →
PDAC	OS	Quartile	II,III,IV	0.304	0.749	.022	2	view →
LUAD	OS	Median	II,III,IV	0.815	0.339	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

L3MBTL2–LSCC (OS)

Open the LSCC breakdown →